Mologic launches clinical trial for validation of point-of-care COPD exacerbation alert system

By |2020-04-06T16:07:22+01:00November 20th, 2019|

Mologic launches clinical trial for validation of point-of-care COPD exacerbation alert system COPE-WEL study aims to validate Headstart® test for early detection and monitoring of pulmonary exacerbation of COPD Headstart is a non-invasive self-test that detects lung biomarkers in the urine Observational, multi-centre validation trial carried out in collaboration [...]

Mologic pushing the boundaries of high sensitivity lateral flow technology – Charlton Morris Life Science

By |2020-04-06T16:03:50+01:00October 7th, 2019|

Being recognised as a company pushing the boundaries of high sensitivity lateral flow technology, Charlton Morris Life Science recently visited Mologic to speak with our Co-Founder and Chief Scientific Officer, Professor Paul Davis, the originator of the Clearblue pregnancy test, the world’s first commercial application of lateral flow technology. [...]

Mologic Developing Sepsis Test Using Multimarker Lateral Flow Technology

By |2020-04-06T16:02:36+01:00September 20th, 2019|

Sep 20, 2019 | Leo O'Connor NEW YORK – Mologic is developing a multimarker point-of care diagnostic test using lateral flow technology that it anticipates launching in Europe next year. The diagnostic test, which is being evaluated as part of a University College London Hospitals (UCLH) study, is part [...]

Mologic and University College London Hospitals collaborating in major clinical trial for early detection of sepsis

By |2020-04-06T16:00:12+01:00September 13th, 2019|

Study aims to develop a rapid point-of-care diagnostic based on multiple biomarkers to detect emergent sepsis Observational study led by Mervyn Singer, Professor of Intensive Care Medicine and Dr David Brealey, Consultant in Intensive Care Bedfordshire, UK, 13 September 2019: Mologic Ltd, a leading developer of lateral flow and [...]

Mologic Develops New Lateral Flow Testing Platform, Partners With West African Dx Center

By |2020-04-06T15:56:12+01:00May 16th, 2019|

NEW YORK (360Dx) – British diagnostics company Mologic has completed development of a next-generation lateral flow testing platform that it claims improves sensitivity significantly. The Bedford, UK-based firm is also working with a new center in Dakar, Senegal, that will deploy new tests based on the platform to support [...]

Mologic achieves breakthrough in ultra-sensitive point-of-care diagnostics and develops new platform technology

By |2020-04-06T15:53:13+01:00May 7th, 2019|

Visually-read device delivers up to 1,000-fold improvement in sensitivity to support surveillance and elimination efforts of global epidemics Since 2016, the Bill & Melinda Gates Foundation has committed $9.7 million to establish and accelerate the CARD technology programme Bedfordshire, UK, 7 May 2019: Mologic Ltd, a leading developer of [...]

Mologic expands US and UK operations

By |2019-04-10T16:27:20+01:00April 1st, 2019|

Strengthens team as part of continued international expansion Bolsters US presence with the opening of subsidiary in Boston, MA Doubles device manufacturing capacity in UK Bedfordshire, UK, 1 April 2019: Mologic Ltd, a leading developer of lateral flow and rapid diagnostic technologies, services and products, today announced it [...]


By |2019-03-14T15:22:04+00:00March 14th, 2019|

Today the Foundation for Innovative New Diagnostics (FIND) is leading a consortium, of which Mologic is part, announced the launch of a new schistosomiasis programme within its neglected tropical disease portfolio. FIND is leading a consortium which along with the WHO is developing novel rapid diagnostic tests for schistosomiasis infection that affects over 206 million people across 78 tropical and sub-tropical countries

Developing In-Home Respiratory, Professional-Use Sepsis Diagnostics for US Launch

By |2018-11-29T09:34:52+00:00October 8th, 2018|

In a recent interview with 360Dx, Mark Davis discussed how Mologic continues to develop it’s strong pipeline of rapid POC diagnostics and begins to look into the North American market for expansion and strategic partners... NEW YORK (360Dx) – Mologic is expanding into the US market and targeting the near-term commercialization of rapid [...]


By |2019-04-10T16:21:18+01:00August 2nd, 2018|

Bedfordshire, UK, 02 August 2018: Mologic Ltd, a developer of powerful, personalised diagnostics to improve the lives of patients, today announced that it has commenced a clinical trial to evaluate the Company’s urine-based diagnostic, HeadsUp, in monitoring pulmonary exacerbation in cystic fibrosis (CF) patients. The study aims to identify [...]

Load More Posts
Go to Top